Technology Offerings

Exploring Ang-(1-7) Agonist Benefits for Acute Lung Injury

With age-adjusted incidences of 86 per 100.000 person-years and overall mortality rates of about 43%, acute lung injury (ALI) and its most severe form, the acute respiratory distress syndrome (ARDS), remains a major cause of death in intensive care. So far, the only evident improvement for the survival of ARDS patients has been achieved by the implementation of minimal invasive ventilation strategies with low tidal volumes as compared to the previously used high tidal volumes. Ang-(1-7) or related agonists may represent a new and promising strategy for the treatment of ALI/ARDS. The present invention provides means and methods for a pharmacological intervention in the patho-physiologic events underlying ALI/ARDS.

Further Information: PDF

ipal GmbH
Phone: +49 (0)30/2125-4820

Contact
Ursula Haufe

Comments (0)

Write a comment